IRadimed Corporation — Q2 2023 Form 10-Q
Business context and period: The unaudited filing covers the quarter and six months ended June 30, 2023. IRadimed develops, manufactures and sells MRI-compatible medical devices, accessories, disposables and services, primarily to hospitals and acute-care facilities.
Financial performance
| Metric | Q2 2023 | Q2 2022 | First half 2023 | First half 2022 |
|---|---|---|---|---|
| Revenue | $16.1 million | $12.7 million | $31.6 million | $25.0 million |
| Gross profit | $12.2 million | $10.1 million | $23.9 million | $19.5 million |
| Gross margin | 75.5% | 79.7% | 75.6% | 78.0% |
| Operating income | $5.0 million | $4.2 million | $9.0 million | $7.2 million |
| Net income | $4.2 million | $3.2 million | $7.6 million | $5.7 million |
| Diluted EPS | $0.33 | $0.26 | $0.60 | $0.45 |
- Q2 revenue increased 26.8%; first-half revenue increased 26.3%. Management attributed growth to patient vital signs monitor and disposable sales, the launch of the Ferro Magnetic Detection System, and, for the first half, higher infusion-pump sales.
- International sales grew faster than U.S. sales: Q2 international revenue rose 67.0% to $3.2 million, while U.S. revenue rose 19.7% to $12.9 million. International sales represented 19.7% of Q2 revenue versus 15.0% a year earlier.
- Q2 device revenue was $10.8 million; disposables, services and other revenue was $4.8 million. The first-half figures were $21.4 million and $9.3 million, respectively.
- Gross margin declined year over year. Management cited unfavorable overhead variances, sales mix and higher raw-material costs; for the first half, the greater international revenue mix also contributed.
- Operating expenses rose overall: Q2 general and administrative expense increased 37.9% and R&D increased 45.2%; sales and marketing expense was down 1.4%. First-half G&A and R&D increased 41.3% and 48.6%, respectively, while sales and marketing decreased 0.5%.
- Other income was $0.34 million in Q2 and $0.68 million for the first half, mainly from interest on money-market fund investments. The first-half effective tax rate was 21.4% versus 20.9% in 2022.
Cash, liquidity and capital
- At June 30, 2023, cash and cash equivalents were $45.8 million, working capital was $58.5 million, total assets were $81.4 million and stockholders’ equity was approximately $69.0 million. Cash was $58.0 million and working capital $68.9 million at December 31, 2022.
- First-half operating cash flow was $8.2 million, compared with $3.1 million in 2022. Investing cash use was $6.9 million, including a $6.2 million land purchase; financing cash use was $13.4 million, primarily reflecting $13.2 million of dividends.
- The company reported no borrowings. Operating lease liabilities totaled $2.25 million; these are lease obligations, not reported debt.
- Inventory increased to $8.4 million from $5.4 million at year-end. Purchase orders for goods and services totaled $14.8 million, with amounts recognized on the balance sheet described as immaterial.
- Management believes cash and cash generated from operations will cover operating needs for at least 12 months. The company plans to use available funds for improvements to the acquired land and capacity expansion.
Outlook, risks and notable items
- For the remainder of 2023, management expects higher revenue than in the comparable 2022 period from medical devices, accessories, disposables and services, and higher operating expenses, primarily G&A and sales and marketing. No numerical guidance was provided.
- The company purchased approximately 26.5 acres in Florida for $6.2 million as a future manufacturing, research-lab and office site.
- The current headquarters and manufacturing facility is leased from an entity controlled by CEO and Chairman Roger Susi. First-half rent paid to that entity was $255,635. This related-party arrangement is an investor-relevant consideration.
- The company accrued approximately $250,000 for various legal matters; management stated that known matters are not expected to materially affect results or financial position.
- Key disclosed risks include FDA and other regulatory approvals, reliance on a limited number of products, sole-sourced components, supply-chain disruption, product liability and competition. The filing reported no material changes to previously disclosed risk factors.
- Disclosure controls were assessed as effective as of June 30, 2023; no material change in internal control over financial reporting was reported.
Important facts for investors to verify
- Whether revenue growth and the faster international contribution continue, and how product mix affects margins.
- Whether raw-material costs and overhead variances ease or continue to pressure gross margin.
- The timing, total cost and expected capacity benefits of the planned facility development, alongside the $14.8 million purchase-order commitments.
- Progress on the next-generation pump and regulatory clearances for products and product candidates.
- The terms and ongoing cost of the related-party facility lease, and developments in the matters underlying the $250,000 legal accrual.
- The pace of cash use, including dividends, capital spending and working-capital investment.